These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 31901236)

  • 1. Sleep dysregulation, memory impairment, and CSF biomarkers during different levels of neurocognitive functioning in Alzheimer's disease course.
    Liguori C; Placidi F; Izzi F; Spanetta M; Mercuri NB; Di Pucchio A
    Alzheimers Res Ther; 2020 Jan; 12(1):5. PubMed ID: 31901236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obstructive Sleep Apnea is Associated With Early but Possibly Modifiable Alzheimer's Disease Biomarkers Changes.
    Liguori C; Mercuri NB; Izzi F; Romigi A; Cordella A; Sancesario G; Placidi F
    Sleep; 2017 May; 40(5):. PubMed ID: 28329084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid eye movement sleep disruption and sleep fragmentation are associated with increased orexin-A cerebrospinal-fluid levels in mild cognitive impairment due to Alzheimer's disease.
    Liguori C; Nuccetelli M; Izzi F; Sancesario G; Romigi A; Martorana A; Amoroso C; Bernardini S; Marciani MG; Mercuri NB; Placidi F
    Neurobiol Aging; 2016 Apr; 40():120-126. PubMed ID: 26973111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
    Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
    Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypothalamic dysfunction is related to sleep impairment and CSF biomarkers in Alzheimer's disease.
    Liguori C; Chiaravalloti A; Nuccetelli M; Izzi F; Sancesario G; Cimini A; Bernardini S; Schillaci O; Mercuri NB; Fabio P
    J Neurol; 2017 Nov; 264(11):2215-2223. PubMed ID: 28900724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Memory performance mediates subjective sleep quality associations with cerebrospinal fluid Alzheimer's disease biomarker levels and hippocampal volume among individuals with mild cognitive symptoms.
    Stankeviciute L; Blackman J; Tort-Colet N; Fernández-Arcos A; Sánchez-Benavides G; Suárez-Calvet M; Iranzo Á; Molinuevo JL; Gispert JD; Coulthard E; Grau-Rivera O
    J Sleep Res; 2024 Aug; 33(4):e14108. PubMed ID: 38035770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid.
    Forlenza OV; Aprahamian I; Radanovic M; Talib LL; Camargo MZ; Stella F; Machado-Vieira R; Gattaz WF
    Bipolar Disord; 2016 Feb; 18(1):63-70. PubMed ID: 26876913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuropsychiatric symptoms differently affect mild cognitive impairment and Alzheimer's disease patients: a retrospective observational study.
    Scaricamazza E; Colonna I; Sancesario GM; Assogna F; Orfei MD; Franchini F; Sancesario G; Mercuri NB; Liguori C
    Neurol Sci; 2019 Jul; 40(7):1377-1382. PubMed ID: 30903419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orexinergic system dysregulation, sleep impairment, and cognitive decline in Alzheimer disease.
    Liguori C; Romigi A; Nuccetelli M; Zannino S; Sancesario G; Martorana A; Albanese M; Mercuri NB; Izzi F; Bernardini S; Nitti A; Sancesario GM; Sica F; Marciani MG; Placidi F
    JAMA Neurol; 2014 Dec; 71(12):1498-505. PubMed ID: 25322206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal changes of CSF biomarkers in Alzheimer's disease.
    Seppälä TT; Koivisto AM; Hartikainen P; Helisalmi S; Soininen H; Herukka SK
    J Alzheimers Dis; 2011; 25(4):583-94. PubMed ID: 21460434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
    Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T
    J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Cerebrospinal Fluid S100B Protein with Core Biomarkers and Cognitive Deficits in Prodromal and Mild Alzheimer's Disease.
    Christl J; Verhülsdonk S; Pessanha F; Menge T; Seitz RJ; Kujovic M; Höft B; Supprian T; Lange-Asschenfeldt C
    J Alzheimers Dis; 2019; 72(4):1119-1127. PubMed ID: 31683478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer's Disease Dementia.
    Mazzeo S; Santangelo R; Bernasconi MP; Cecchetti G; Fiorino A; Pinto P; Passerini G; Falautano M; Comi G; Magnani G
    J Alzheimers Dis; 2016 Oct; 54(4):1495-1508. PubMed ID: 27589522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease.
    Sala I; Illán-Gala I; Alcolea D; Sánchez-Saudinós MB; Salgado SA; Morenas-Rodríguez E; Subirana A; Videla L; Clarimón J; Carmona-Iragui M; Ribosa-Nogué R; Blesa R; Fortea J; Lleó A
    J Alzheimers Dis; 2017; 58(3):909-918. PubMed ID: 28527215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer's disease.
    Alexopoulos P; Werle L; Roesler J; Thierjung N; Gleixner LS; Yakushev I; Laskaris N; Wagenpfeil S; Gourzis P; Kurz A; Perneczky R;
    Alzheimers Res Ther; 2016 Dec; 8(1):51. PubMed ID: 27931251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association between biomarkers in cerebrospinal fluid and structural changes in the brain in patients with Alzheimer's disease.
    Li X; Li TQ; Andreasen N; Wiberg MK; Westman E; Wahlund LO
    J Intern Med; 2014 Apr; 275(4):418-27. PubMed ID: 24237038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.
    Popp J; Wolfsgruber S; Heuser I; Peters O; Hüll M; Schröder J; Möller HJ; Lewczuk P; Schneider A; Jahn H; Luckhaus C; Perneczky R; Frölich L; Wagner M; Maier W; Wiltfang J; Kornhuber J; Jessen F
    Neurobiol Aging; 2015 Feb; 36(2):601-7. PubMed ID: 25435336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High tau levels in cerebrospinal fluid predict nursing home placement and rapid progression in Alzheimer's disease.
    Degerman Gunnarsson M; Ingelsson M; Blennow K; Basun H; Lannfelt L; Kilander L
    Alzheimers Res Ther; 2016 Jun; 8(1):22. PubMed ID: 27263933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
    Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
    J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.
    Podhorna J; Krahnke T; Shear M; Harrison JE;
    Alzheimers Res Ther; 2016 Feb; 8():8. PubMed ID: 26868820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.